Noteworthy News Articles on Mental Health Topics, July 29, 2001
Critics: Mentally Ill Needs Unmet
Sara Scott, Ann Arbor News- 7/29/2001
LANSING--Once seen as the salvation of the mentally ill,
deinstitutionalization today is almost a dirty word. Over the last three decades,
Michigan has reduced the number of mentally ill in state psychiatric institutions from
17,000 to just over 1,000 last year. But what began as a humane movement to
mainstream the mentally ill into the community started to backfire in the 1990s, critics
say.
"I think we all jumped on the deisntitutionalization train, but
we've taken it too far," said Kathleen Gross, the executive director of the Michigan
Psychiatric Association which represents 900 psychiatrists statewide. "We have
made so many drastic changes to our system, we've lost our focus."
During the last decade, under Gov. John Engler's administration,
Michigan has closed 10 state-run psychiatric hospitals, reducing the number of
hospitalized mentally ill patients from 2,925 to 1,043. There are now just five
hospitals for the mentally ill. The result, critics say, are overburdened local
Community Mental Health offices, which provide treatment and services to the mainstreamed
mentally ill. Sometimes, the mentally ill end up homeless, or in jail or prison.
The situation has pushed Michigan's major mental health advocacy
associations to call for a stop to the closing of psychiatric hospitals--and even the
reopening of some. Specifically, they are asking the Department of Community Health
to add 400 long-term beds throughout the state. There's no price tag on the plan,
but there does seem to be legislative support for increasing bed space. Earlier this
year, 30 Democratic House members introduced a resolution calling on the governor to
reopen some of the closed hospitals. That bill is languishing in a GOP-controlled
committee. Another new bill calls for creating a Community Mental Health ombudsman.
"The community can't handle everything, there are some people who
can't succeed in a community-based setting," said Mark Reinstein of the Mental Health
Association in Michigan, an advocacy group. "They need more supervision, they
need more structure." Some Community Mental Health officials agree, saying they
struggle to find bed space for patients. "It's a day-to-day thing," said
Dan Russell, the director of the Genesee County CMH. "The criteria (for
admittance to a hospital) hasn't changed so much as the interpretation of that criteria
has changed. A person who 10 years ago would have no problem getting in, probably
couldn't today."
Law enforcement officials say the mentally ill have also flooded
Michigan's jails. A 1997 survey of 60 counties found that 8.1% of jail inmates had a
serious mental illness. The survey was put together by former state Rep. Liz Brater,
D-Ann Arbor, with help from the Michigan Sheriff's Association and the Alliance for the
Mentally Ill. "These people end up in the county jail, and (jail personnel) do
the best they can, but they don't have the resources to deal with them," said Genesee
County Circuit Court administrator Barbara Menear, who also oversees the county's public
defender program.
Still, the percentage of mentally ill receiving treatment in the state
prison system has remained relatively level through the 1990's. Of the 46,000
prisoners in Michigan, 6.1% receive mental health services. That's up just one
percentage point since 1997, according to the Department of Corrections. "This
administration has labored intensively to offer a more humane, community-based approach
for those with mental illness," said Corrections spokesman Matt Davis. "I
don't think you can say that we simply shifted the mentally ill from state institutions to
state prisons."
But advocates say the department's numbers don't reflect reality.
"That's a very clever way of presenting the data. They're saying these are the
number of inmates receiving treatment, but the real question is how many need
treatment," Reinstein said. State officials note the system has undergone
radical changes since 1990. "In 1990, the system was centered around our
hospitals. Today, it's centered on community-based care, where patients have options
and choices about treatment and services," said Jeff Patton, the deputy director of
mental health and substance abuse services.
Launched in the mid-1960s, deinstitutionalization was a national
movement to correct a social injustice: The practice of simply keeping the mentally
ill in institutions. With the right medications and community support, proponents
argued, most of the nation's mentally ill could lead productive lives in their own
community. From there, the Community Mental Health concept was born. "It
was one of those philosophies that had appeal for everyone," said Reinstein of the
Mental Health Association of Michigan. "It was attractive from a programmatic
and clinical standpoint. And, it's attractive from a fiscal standpoint for
politicians and government." Michigan began closing psychiatric hospitals and
mainstreaming the mentally ill and the developmentally disabled in 1972. Patients
instead received medications, treatment and services through their local Community Mental
Health center. But the state went too far in the 1990s with community-based care,
advocates say. They hear from more and more families who are unable to find
long-term residential care for family members.
Consider Pamela Skinner, of Troy, who tried for three years to get her
11-year-old daughter, Amber, admitted to Hawthorn Center in Northville. Diagnosed
with bipolar disorder in 1996, Amber had assaulted her sister and threatened to kill
herself and others. One day, she snuck into a neighbor's house and snatched the
woman's 1-year-old daughter, bringing her home, Skinner said. No harm came to the
baby, but it was still very disturbing. "She was very violent, very
out-of-control," Skinner said. "She fit all of the criteria for long-term
care, but they wouldn't take her." Amber was finally admitted to Hawthorn two
months ago. She is scheduled to come home in January 2002.
The department can't speak to individual cases for confidentiality
reasons, but Patton makes no apologies for the rigid restrictions on admittance to a state
psychiatric hospital, particularly for children. "I just don't believe that it
should be easy for a child to be hospitalized," Patton said. "I've seen
what happens once you take the child out of the home, things in the home begin to
change." But critics charge that local Community Mental Health boards are
increasingly asked to do more, with fewer resources. Although funding for mental
health services has increased from $1.28 billion in 1990 to $2.1 billion today, advocates
say it hasn't even kept pace with inflation. Meanwhile, caseloads are up. From
1991 to 1999, the number of mentally ill people receiving CMH services increased from
134,377 to 171,190.
State officials say they have no intention of going back to a
hospital-centered approach to mental health treatment. Patients don't want that
either, they say. "If you listen to the consumers--not the advocates--they
don't want to be locked up," Patton said. "They want jobs, they want to go
to school, they want to live in their community." But the advocates say the
state has lost sight of the original intent of deinstitutionalization--letting people live
in the community, but effectively treating them, as well. "It's not a question
of correcting what was at the time a social disgrace, when people were simply warehoused
in institutions," said Susan McParland, the executive director of the Michigan
Association of Children with Emotional Disorders. "What Michigan is dong now
can't even be called, 'deinstitutionalization.' "
The Alchemy of OxyContin
Paul Tough, The New York Times Magazine- 7/29/2001
Paula is taking me on a driving tour of Man, the tiny West Virginia town where she has
spent her entire life. Because I don't know my way around the hollows and gullies and
creeks that carve through these hills, Paula is at the wheel. And because Paula isn't a
morning person, we've set out on our tour at midnight. It's dark; the only illumination
comes from our headlights cutting through the mist that rolls down from the hills.
The tour Paula is leading isn't sanctioned by the local chamber of
commerce; there are no stops at Civil War plaques or scenic vistas. It's a pillhead tour:
an addict's-eye view of the radical changes that a single prescription drug called
OxyContin, has brought to the town of Man OxyContin abuse started in remote communities
like this one more than two years ago; more recently, it has spread beyond its origins in
Appalachia and rural Maine to affect cities and suburbs across the eastern United States.
I came to Man to try to understand how America's latest drug problem started, to see its
roots and trace how it has spread. "That's my best friend's trailer right
there," Paula says, pointing out a comfortable looking single-wide across the creek.
"She's somebody that you couldn't look at and know she was an oxy addict. She was a
cheerleader in junior high. She's married. You can't just look at somebody and tell."
A few years ago, Paula says, Man was like any small town in America:
you could buy a variety of illegal drugs, as long as you knew the right person to talk to.
Pot was big; there was occasionally some cocaine around and a few pills for recreational
use. Fads would come and go. But these days, she says, the only drug for sale in Man is
OxyContin, a narcotic painkiller that users crush to disable its patented time-release
mechanism and then snort or inject for a powerful and immediate opiate high. Legally, it's
sold only by prescription for the treatment of chronic pain. In practice it's available
just about everywhere around here, immediately, for cash. The going rate is a dollar a
milligram, or $40 for a 40-milligram pill.
Paula is a thoughtful, good-natured 24-year-old with wispy blond hair,
serious eyes and faded jeans. She's fidgety; as she drives with one hand, she's rummaging
through her handbag with the other, looking for her pack of Marlboro Lights. She finds
them, removes one and stabs the dashboard lighter. "I'll show you some places over
here," she says, as she turns her car off the main road, over a short bridge and down
into a rough indentation that holds a couple dozen trailers and prefab homes. "This
is Green Valley. We just call it the valley. It's a pretty good neighborhood," she
says, then interrupts herself. "Well, except that's a dealer there."
She points to a trailer with a Chevy pickup out front and a light
burning inside. I crane my neck to get a look at a real-life drug den, but the tour has
already moved on. Paula is pointing out a trailer on the other side of the road:
"That's a small-time dealer there, nothing big," she says. Then she points to
another one, and then another: "That's a dealer. . . . That's a small-time dealer. .
. . That's a dealer. . . . Her son's a dealer, but I don't know if he lives there. ... He
uses, that boy in there. . . . They use really, really big."
We're driving slowly around the circular dirt road that is the only
path through Green Valley. The neighborhood doesn't feel dangerous - no graffiti, no pit
bulls, no broken bottles lying around. Still, Paula is pointing out criminal activity in
every second home, peering through the front windshield and gesturing left and right:
"They used to deal, too, but they don't no more. ... They deal. ... There's some
dealers up through there, one or two, nothing big. ... This boy that lives here deals. . .
. They deal, in that trailer there."
The first time Paula did an oxy (as she calls the pills), in the summer
of 1999, it didn't do much for her. "That first 10-milligram pill, I didn't really
feel nothing off it," she says. "But the second time I did it, I did two 20's,
and I was high." She liked the effect. "When you get that oxy buzz,"
she says, "it's a great feeling. You're happy. Your body don't hurt. Nothing can
bring you down. It's a high to where you don't have to think about nothing. All your
troubles go away. You just feel like everything is lifted off your shoulders."
What Paula calls "that oxy buzz" comes from OxyContin's only
active ingredient: oxycodone, an opioid, or synthetic opiate, developed in a German
laboratory in 1916. Chemically, it is a close relative of every other opium derivative and
synthetic: heroin, morphine, codeine, fentanyl, methadone. The narcotic effects that Paula
is describing are the exact same ones that have drawn people to opiates for centuries. And
just as every opiate does, oxycodone creates a physical dependence in most of its users
and a powerful addiction in some of them. "At first you do them to get high,"
Paula says, "and then after you're addicted to them you don't to them to get high;
you do them to survive. You do them to feel normal." At her peak, she says, she was
snorting four or five 80-milligram pills a day.
The earliest reported cases of oxycontin abuse were in rural Maine,
rust-belt counties in western Pennsylvania and eastern Ohio and the Appalachian areas of
Virginia, West Virginia and Kentucky. The problem traveled through these regions, as
friends told friends and the word spread from town to town, county to county, up and down
the Appalachians. There are a few defining characteristics that the first affected regions
share: they're home to large populations of disabled and chronically ill people who are in
need of pain relief; they're marked by high unemployment and a ack of economic
opportunity; they're remote, far from the network of interstates and metropolises through
which heroin and cocaine travel; and they're areas where prescription drugs have been
abused -- though in much smaller numbers -- in the past. "There's always been a
certain degree of prescription drug abuse in this area," says Art Van Zee, a
physician in Lee County, Va., "but there's never been anything like this. This is
something that is very different and very new, and we don't understand all the reasons
why. This is not just people who have long-term substance-abuse problems. In our region
this is young teenagers, 13- and 14-year-olds, experimenting with recreational drug use
and rapidly becoming addicted. Tens of thousands of opioid addicts are being created out
there."
In Man, Paula said, it was like OxyContin came out of nowhere. One day
no one had heard of oxys, and a month later, the pills had become a way of life for
hundreds of locals. It became so easy to buy OxyContin in and around Man, Paula said, that
until recently, she never really thought about the fact that everyone involved was
breaking the law. "Buying pills never seemed illegal," she said. "It just
didn't feel like it was wrong." There aren't lookouts involved, or secret passwords
or elaborate drop sites: when Paula wants to buy an OxyContin pill, she simply drives to a
dealer's house and knocks on the front door in broad daylight. If she knows the dealer
well enough, she'll go on in and snort the pill there, just to be neighborly. If not,
she'll hand over the cash, put the pill in her pocket and drive away. Sometimes she'll be
the only person there; other times, there will be a dozen cars lined up out front.
The dealers have the benefit of a captive market: OxyContin, like any
opioid, is very difficult to quit abusing. And given the pill's ubiquity here in Man and
the fact that the nearest rehab clinic is two hours away, this is an unusually hard place
to quit using it. Nonetheless, Paula is trying. Six months ago she and her best friend
decided they were going to quit cold turkey. They took a couple of days off work, locked
themselves in her friend's trailer and started to detox. "That was the worst three
days of my life," Paula said. `Honestly, I prayed to God to let me die. That's how
bad it is. Your stomach hurts; you get really bad headaches, you get diarrhea. You want to
throw up. You get really depressed. If you can get past the third day or the fourth day,
you're pretty much fine, but most people don't make it." Paula and her friend didn't
make it: at the end of the third day, they went out and got a pill. A few months ago,
OxyContin abuse was considered a regional problem, labeled "hillbilly heroin"
and confined to areas far from the nation's population centers. This year, though, abuse
of OxyContin has started to move away from its backwoods origins and into metropolitan
areas on the East Coast, into the Deep South and parts of the Southwest and into suburban
communities throughout the Eastern United States. In Miami-Dade County, there have been 11
overdose deaths so far this year in which oxycodone was the probable cause, according to
the county medical examiner. There have been 11 more in Philadelphia, according to the
medical examiner there. Police in Bridgeport, Conn., arrested a local doctor in July for
prescribing tens of thousands of OxyContin tablets to patients, often, they say, without
any medical examination at all. And in the suburbs of Boston, police say more than a dozen
pharmacies have been held up by a gang of young men wearing baseball caps and bandannas,
looking for OxyContin.
In many ways, the spread of OxyContin abuse closely resembles another
recent drug epidemic. In the early 1990's, the Medellin and Call cartels controlled
cocaine and heroin distribution in the United States. Cocaine was selling well, but there
was a marketing problem with heroin: it could only be injected, and many people, even
frequent drug abusers, are reluctant to stick needles in their arms.
The Colombians' solution to this problem was to increase the purity of
the heroin they were bringing into the United States until it was potent enough to snort.
They were then able to use their existing cocaine-trafficking network in the Eastern
United States to get heroin onto the street in powder form. Cocaine users, who were used
to the idea of buying and snorting a white powder, experimented and became addicted. As
their tolerance increased, these new heroin snorters overcame their aversion to needles
and soon turned into heroin injectors. Similarly, there were plenty of oxycodone users in
Appalachia before OxyContin came along. Many of the OxyContin addicts I spoke to in
Kentucky and West Virginia used to snort or chew a mild oxycodone-based painkiller called
Tylox. They said they found the pills somewhat euphoric and not very addictive -- each
Tylox contains just 5 milligrams of oxycodone, along with 500 milligrams of acetaminophen.
When OxyContm arrived on the scene, in pills containing 20, 40 and 80 milligrams of
oxycodone, it marked a jump in purity similar to that of early-90's heroin -- and again,
casual users started snorting, and then shooting, a powerful opioid.
Although heroin and OxyContin have a similar unhappy effect on the
lives of people addicted to them, there is a critical and simple difference between the
two: heroin is illegal; OxyContin, when used as directed, is legal. More than that: the
pill is government-approved. It is made by Purdue Pharma, a successful and well regarded
pharmaceutical company headquartered in Stamford, Conn. It is prescribed to a million
patients for the treatment of chronic pain, and it is closely regulated at every stage of
its manufacture and distribution by the Food and Drug Administration and he Drug
Enforcement Administration.
This fact has meant a major conceptual shift for law-enforcement
officials who are used to combating narcotics produced by international drug lords, not
international corporations. Terry Woodworth, the deputy director of the D.E.A.'s office of
diversion control, says the spread of OxyContin has posed a challenge to the D.E.A.'s
traditional methods: "Instead of using the normal law-enforcement techniques -- like
going to the source and attempting to eradicate or destroy the criminal organization
producing the drug and immobilize its distribution networks and seize all is assets -- you
have a very different situation in a legitimate industry, in that your manufacture and
distribution is legal." Scott Walker, the director of Layne House, a drug treatment
facility in Prestonsburg, Ky., puts it more concisely: "You don't have the Coast
Guard chasing OxyContin ships," he says. "This isn't something you can top at
the border. It's growing from within."
Part of what makes the spread of OxyContin abuse so difficult to track,
et alone to stop, is that the drug moves not physically but conceptually. When crack
cocaine spread from the big cities on either coast toward the center of the country, it
traveled gradually, along Interstates, city by city. OxyContin abuse pops up suddenly, in
unexpected locations: Kenai; Alasska; Tucson; West Palm Beach, Fla. At the Gateway
Rehabilitation Center n Aliquippa, Pa., a suburb of Pittsburgh, Jay, a recovering
OxyContin addict and a former small-time dealer, offered an explanation for OxyContin's
sudden geographical shifts. "It's the idea that passes on," he told me. `That's
how it spreads. There aren't mules running the drug across the country. It's dealt by word
of mouth. I call a friend in Colorado and explain it to him: 'Hey, I've got this crazy
pill, an OC 80, an OC 40. You've got to go to the doctor and get it. Tell him your back
hurts."'
Jay is 26, a college graduate and former nurse. He started doing oxys
in 1999 and his consumption quickly rose to 240 milligrams a day. He was clean when we met
and trying to stay that way. But when he talked about the drug's potential as a small
business, he couldn't help getting excited. "I could go to California or Las Vegas
and say, Hey, I was getting OC's prescribed to me in Pennsylvania; I'm going to get them
in Las Vegas,"' he said. "And then if I wanted to sell them, I could sell them
there. I'd start out and sell them for 10 bucks apiece. Get people hooked on them, then
sell them for 50 bucks apiece. It's experienced word of mouth. I've experienced the drug,
therefore I know how to describe it to you."
Unlike heroin, Jay explained, OxyContm doesn't require investment or
muscle or manpower to move across the country. OxyContin abuse is a a contagious idea-a
meme, if you will. Because OxyContin, the medicine, is readily available in
pharmacies everywhere all it takes to bring OxyContin, the drug, to a new place is a
persuasive talker like Jay. A powerful recreational narcotic can now travel
halfway across the country in the course of a phone call.
In order to understand the particular dilemma of OxyContin, you need to
understand the longfought war among doctors over pain and addiction. For centuries, opium
arid its derivatives have been considered a double-edged sword -- the most effective
painkiller on earth and also the most addictive substance. For most of the 20th century,
opiates were considered too dangerous to use in all but the most critical pain treatments.
The assumption was that their medical use would inevitably lead to addiction. In the late
1980's, for the first time, public and medical opinion began to swing decisively in the
other direction. Patient advocates and pharmaceutical companies, bolstered by studies
showing that there were vast numbers of cancer patients whose pain was being undertreated,
encouraged the medical community to rethink its approach to opioids, especially in the
management of cancer pain. Their campaign was persuasive. Between 1990 and 1994, morphine
consumption in the United States rose by 75 percent, and in 1994, the Department of Health
and Human Services issued new clinical guidelines encouraging the use of opioids in the
treatment of cancer pain.
Purdue Pharma was a leading player in the pro-opioid campaign. The
company contributed generously to patient-advocacy organizations, including the American
Pain Foundation, the National Foundation for the Treatment of Pain and the American
Chronic Pain Association, and underwrote dozens of scientific studies on the effectiveness
of opioids in the treatment of pain. In 1985, the company began marketing MS Contin, a
time-release morphine pill that was used to treat cancer pain. As attitudes on opioids
shifted, Purdue began to promote MS Contin for non-cancer pain as well.
Dr. Russell Portenoy is chairman of pain medicine and palliative care
at Beth Israel Medical Center in New York City, and the co-author of a groundbreaking 1986
study that supported the long-term use of opioids to treat non-cancer pain. "Between
1986 and 1997, within the community of pain specialists, there was increasing attention on
the role of opioids," Portenoy says, "but there was relatively little diffusion
of that idea to family doctors and other non-specialists." That began to change,
Portenoy says, with the F.D.A.'s approval of OxyContin in 1995. "There was a sea
change that occurred with the release of this drug," Portenoy says. For the first
time, general practitioners began to prescribe strong, long-acting opioids to treat
chronic non-cancer pain. Portenoy says the change was due to four factors that came
together at about the same time. "The reasons were partly cultural -- the attitudes
of the medical and regulatory communities had been gradually shifting for a decade. They
were partly medical -- studies had been coming out showing that patients with low back
pain, chronic headaches and neuropathic pain might benefit from long-term opioid therapy.
They were partly pharmacological -- OxyContin made it easier and more convenient for
patients to receive long-term opioid therapy. And they were finally related to marketing,
because Purdue Pharma was the first company to advertise an opioid pill to general
practitioners in mainstream medical journals."
In addition to those doctor-directed ads in magazines like The Journal
of the American Medical Association, the company began an innovative indirect-marketing
campaign just before OxyContin's release. Because of F.D.A. regulations on the marketing
of narcotics, the company was unable to use direct-to-consumer advertising, as other
pharmaceutical companies were beginning to do for antidepressants and prescription allergy
medications. So Purdue decided to concentrate on what they call "non-branded
education." Just as Nike advertises the concept of sports instead of shoes, so Purdue
would market the concept of pain relief to consumers, but not OxyContin. In 1994, the
company launched Partners Against Pain, a public-education program that at first
concentrated on cancer pain and later expanded to include other forms of long-term pain.
Through videos, patient pain journals and an elaborate Web site, Purdue promoted three
ideas to doctors and patients: that pain was much more widespread than had previously been
thought; that it was treatable; and that in many cases it could, and should, be
treated with opioids. Partners Against Pain didn't promote OxyContin specifically; the
company's marketers knew that simply expanding the total market would also increase their
bottom line.
OxyContin was seen by many doctors as the solution to the long rift
between pain specialists and addiction specialists. Purdue Pharma believed that
OxyContin's time-release function would mean a much lower risk of addiction than other
opioid medications. According to a principle known as the "rate hypothesis," the
rate at which an opioid enters the brain determines its euphoric effect, and also its
addiction potential. This is why injecting a narcotic produces a more powerful high, and
addiction risk, than snorting it or swallowing it. Because OxyContin, taken whole,
provides a steady flow of oxycondone over an extended period, the high it produces is
diminished, as is the risk of addiction.
Before OxyContin, narcotic painkillers were prescribed mostly by
oncologists and pain specialists. Purdue believed that OxyContin's time-release safeguards
made it appropriate for use by a much broader array of medical professionals. The company
began promoting OxyContin to family doctors and local pharmacists nationwide through a
network of hundreds of field reps who emphasized, in their office visits, the idea that
OxyContin presented a lower addiction risk than other opioid medicines.
Over the next few years, sales of OxyContin exploded. OxyContin
prescriptions have more or less doubled in number each year since its release; the
company's revenues from the pill jumped to $1.14 billion in 2000 from $55 million in 1996.
Last year, doctors wrote more than six and a half million OxyContin prescriptions, and
OxyContin ranked as the 18th best-selling prescription drug in the country (as measured by
retail sales) and the No. 1 opioid painkiller. The company grew along with its main
product's sales; between 1998 and 2000, the Purdue work force expanded to nearly 3,000
employees from 1,600.
Purdue's attempt to expand the opioid marketplace beyond cancer
patients was also remarkably successful. Five years ago, cancer patients were still the
main market for long-acting opioids, but oncologists accounted for only 3 percent of the
OxyContin prescribed last year. The largest single group of OxyContin prescribers is now
family physicians, who account for 21 percent of the total.
According to Portenoy, this change in the number and kinds of doctors
prescribing OxyContin is fundamentally linked to the spread of OxyContin abuse. "It's
not the drug, per se," Portenoy says. "It's rapidly expanding access, plus the
reality of doctors prescribing it who may not have the skill set required to prescribe it
responsibly."
Purdue's field reps were the first wave of OxyContin apostles,
spreading word of the pill's effectiveness door to door-doctor by doctor, pharmacist by
pharmacist., But Purdue's officially sanctioned word-of-mouth marketing campaign was
followed by another, unsanctioned one. This time the news was that the miracle pill had an
Achilles' heel, that its time-release matrix could be eliminated completely in a matter of
seconds by the simple act of crushing the pill with a spoon, a lighter, even a thumbnail,
and that the resulting powder, when snorted or mixed with water and injected, produced a
very potent high. The apostles this time were not Purdue's field reps but casual drug
abusers throughout the Eastern United States. And just like Purdue's, their marketing
campaign was enormously successful.
In a steel-mill suburb northwest of Pittsburgh, the leader of the
second wave of OxyContin apostles was Curt, a young man who in 1998, at the age of 23,
found himself kicked out of the Air Force and living back in his hometown. He worked the
midnight shift running cranes at the mill, and he dealt a little marijuana during the day.
He was part of a "drug community," as he calls it, 20 or so people who worked
together, hung out together, went to parties and concerts and smoked a lot of pot. Every
couple of months someone would land a prescription for Percocet or Vcodin, and they'd sell
the pills to friends for $5 apiece, a cheap and mild high.
In April 1999, someone in his circle was prescribed OxyContin. Curt
assumed that it was just like any other pain pill. "Everybody thought at first that
they were like a Percocet," Curt says. "Nobody understood how many milligrams
were really in these things. People were selling them like an expensive Percocet" --
for $10, in other words, instead of $5 -- and swallowing them whole. At a party, Curt
figured out the trick of crushing the pill and snorting the powder, and he quickly spread
the word. "I showed a lot of people," Curt says. "At first they were like,
`You're crazy.' But then they'd do it, and that would be it. People tell me now, Yeah,
you're the one who showed me how to snort this thing."
Oxys quickly became very popular in Curt's circle of friends, and Curt
found a comfortable niche for himself between supply and demand. "I knew people all
over the county that were getting prescriptions," he says. "They'd call me and
say, I'm getting OC's now and I want to get rid of them. They knew there was money there,
but they didn't know who to sell to. They usually gave me a heck of a deal. I'd get them
all for maybe $10" per 40-milligram pill. "I'd sell them for $20, so for every
one I sold, I made one. And then I'd give them their money and the next month I'd get
their scrip again." At that rate, he could make $900 off a 90-pill bottle. But he
wasn't in it for the profit; he was in it for the pills. "I didn't need money,"
he explains. "I worked at the mill. I was always doing it just for the free
drugs."
Before long, he had 10 people giving him their pills to sell, mostly
women in their 30's and 40's on welfare or disability. (Patients on Medicaid pay just a
dollar for a $250 OxyContin prescription.) "It's so weird the people that got into
this," Curt says. "Some of them were innocent mothers. I had one that was in her
60's. She never did drugs. She'd sell every last one of her pills, and it would pay for
all her other medication." Curt would keep careful track of which day of the month
each of his suppliers filled her prescription. ` A lot of times I would drive them to the
pharmacy," he says. "I'd always get a couple of pills for that."
One of the most valuable -- and closely guarded -- resources in the
local OxyContin economy was a doctor who was willing to write an OxyContin prescription
without asking too many questions. "It's a slow process, breaking a doctor in,"
Curt explains. "You've got to know how to work him. I'd say: `I can't take the
Vcodins and the Percocets because they're hurting my stomach. Do they have anything
that's, like, time released?' The doctor goes, 'Oh, you know what, they've got this new
stuff called OxyContin.' And I'd say: 'Oh, yeah? Wow, how's that work?"' Some local
doctors, Curt says, knew exactly what was going on, but they needed the business. One
started handing out monthlong OxyContin prescriptions every two weeks.
On the demand end, Curt had between 25 and 50 steady customers. "I
had a cell phone at that time, so I was doing a lot of driving," he says.
"People would gather at their houses, and they'd bring all their friends over, 10 of
them that'd use it. They'd all gather when they knew I was coming, because they wanted the
pill immediately."
Curt has been in recovery for a few months now; since he got out of
rehab, he's been cut off from almost all his old friends, and he fills his spare time
fixing up his sister's house, fishing and reading up on psychology, which he plans to
begin studying this fall. He's a man of boundless energy and focus, and he has taken to
the 12-step process with an unusual intensity; in his first 60 days clean, he told me, he
attended 138 Narcotics Anonymous meetings. That same energy served him well back in his
oxy days, when he was cutting steel at the mill all night and driving around making
pickups and deliveries all day. The pills themselves, he says, helped him keep going.
"I could go get two hours of sleep, wake up, do a pill and continue on from
there," he says.
It was only a couple of months after OxyContin arrived in town that
Curt and most of his customers realized they were addicted. At first, they were happy just
to take a pill whenever one was around, for fun, but soon they found themselves
experiencing severe withdrawal symptoms if they didn't have a pill every day. Everyone's
tolerance built up quickly -- one week they were able to get by on a 20 a day, the next
week they'd need a 40, and a couple of weeks later, it had to be an 80. "No one knew
what was going on," Curt says. "These are a bunch of pot smokers, drinkers, just
mellow people. This drug just took us by storm. A whole community, at least a hundred
people I know around here. They're all into the addiction. These are guys I used to smoke
pot with and drink beer with in the woods. I grew up with them all, having parties and
that. And now there's not one of them -- not one of them -- that don't use pills."
Purdue Pharma wasn't aware of significant problems with OxyContin abuse
until April 2000, when a front-page article in The Bangor Daily News, claiming that
OxyContin "is quickly becoming the recreational drug of choice in Maine," landed
on the desk of Purdue's senior medical director, Dr. J. David Haddox. In the summer of
2000, the company formed a response team, made up of medical personnel, public relations
specialists and two of the company's top executives, which has guided the company's
OxyContin campaign ever since.
It's fair to say that in public relations terms, Purdue's reaction to
the OxyContin problem has been less than successful. As recently as six months ago, the
company had a considerable supply of good will in the media, the government and the
affected communities; it is now facing 12 separate potential class-action suits from
former patients, as well as one from the attorney general of West Virginia; formerly
sympathetic community leaders in Appalachia and Maine have grown increasingly skeptical of
the company's approach; and in separate Congressional testimony, Attorney General John
Ashcroft called OxyContin a "very, very dangerous drug," and Donnie Marshall,
then head of the D.E.A., said in May that unless he received "more cooperation"
from Purdue, he was "seriously considering rolling back the quotas that D.E.A. sets
.. . to the 1996 level," which would have meant a 95 percent cut in production.
Purdue's PR. problems seem rooted in the company's deep-seated belief
in the inherent safety of and public need for its product. It is an article of faith for
the company that illegal traffic in its drug is the work of "bad guys" and
"professionals in Haddox's words. In fact, Purdue says that its internal data
indicate that the levels of OxyContin abuse in the country are no greater than expected.
"We have had increased numbers in the last year or so," I was told by Robert
Reder, Purdue's vice president of medical affairs and worldwide drug safety, "but our
estimation is that they're commensurate with the distribution of the drug." The abuse
situation, according to Reder's numbers, is normal. (Government statistics indicate that
as of 1999, 221,000 Americans had abused OxyContin.) The real victims, the company says,
are their "legitimate patients," who would be denied OxyContin if its
distribution were restricted.
In March, Purdue announced a 10-point plan to combat OxyContin abuse.
The plan includes tamper-resistant prescription pads for doctors, anti-diversion brochures
and educational seminars for doctors and pharmacists in affected areas, an initiative to
combat smuggling of OxyContin from Mexico and Canada and a donation of $100,000 to a
Virginia group for a study of prescription-monitoring programs. To Purdue, the plan is
generous and well focused; to people in the communities where abuse is widespread, it
seems like a way for the company to avoid the real problem. I spoke several times this
spring and summer to Debbie Trent, a professional counselor in Gilbert, W Va., who runs
the local anti-drug community group called STOP (Strong Through Our Plan). In our first
conversation, she was scrupulously cautious and polite when she spoke about Purdue Pharma,
saying, "I don't want STOP to be seen as fighting OxyContin." During STOP's
first few months, Haddox addressed her group twice.
When we spoke in April, though, Trent told me that she had come to
believe that the company's 10-point plan was addressing the wrong problems -- prescription
fraud and international smuggling, for example, when what Gilbert really needed was a way
to get immediate treatment for its many addicts. "I read about the tamper-proof
prescription pads and I think, Give me a break!" she said. "That seems like such
a little thing. It seems so minute in comparison to the scope of the problem. It's almost
intentionally missing the point. Rather than prescription pads, I would like to see
something done in rehab, something where they're making an effort to help these folks get
better."
Similar sentiments were expressed in Maine in July, when Purdue
announced its latest solution to the OxyContin problem: a $100,000 grant to start a
"mini-M.B.A." program in high schools. This fall, Purdue will send 20 teachers
from some of the most affected counties in Appalachia and Maine to New York for training
by the National Foundation for Teaching Entrepreneurship. When they return to their
schools, they will teach students how to formulate a business plan and invest in the stock
market. The idea is to "provide these kids with a sense of hope," according to a
Purdue spokesperson. A Maine school administrator was quoted in The Boston Globe asking
why the company "wouldn't have come up here and asked us what we want"; if
anyone had, she said, she would have asked for money for the treatment of addicts rather
than entrepreneurial training.
Again and again, Purdue has apparently been blindsided by criticism. At
a news conference in Alabama attended by parents whose teenage children had died from
OxyContin overdoses, Gov. Don Siegelman interrupted a Purdue doctor who was going point by
point through Purdue's 10-point plan. "I find this very offensive, and I want you to
stop," he said as the doctor stood open-mouthed in front of the television cameras.
"We've had enough public relations and enough sugar-coating of this issue and quite
frankly, as governor, I am fed up." In March, Haddox had what he thought was a
cordial and cooperative meeting with Attorney General Darrell V McGraw of West Virginia to
discuss the company's plan to combat drug abuse. Less than three months later, McGraw
filed a lawsuit against Purdue, charging the company with "highly coercive and
inappropriate tactics to attempt to get physicians and pharmacists to prescribe OxyContin
and to fill prescriptions for OxyContin, often when it was not called for," and
seeking millions of dollars in compensation for state medical costs.
In the meantime, the lack of coordination between Purdue and the
government agencies that regulate it has had serious repercussions in affected
communities, as local police, small-town mayors and individual doctors and pharmacies have
been forced to make up their own policies on the fly. Six states -- Florida, Maine,
Vermont, West Virginia, Ohio and South Carolina -- have introduced regulations making it
harder for Medicaid recipients to receive OxyContin. After the recent spate of pharmacy
robberies near Boston, dozens of drug stores in Massachusetts pulled OxyContin from their
shelves -- only to be ordered by the state pharmacy board to begin carrying the drug
again. In the small town of Pulaski, Va., the police have instituted a program in which
patients picking up OxyContin prescriptions from local pharmacies must give their
fingerprints, a development that has alarmed civil liberties advocates. Doctors in many
states, sometimes fearing reprisals from the D.E.A., have refused to prescribe OxyContin
even to patients clearly in need.
Purdue's executives see the company as an unwitting victim of criminal
activity -- not unlike Johnson & Johnson in 1982, when seven people were killed by
Extra-Strength Tylenol tablets that had been laced with cyanide. The company's critics
prefer to compare Purdue to tobacco companies and handgun manufacturers, who are
increasingly likely to be found liable for deaths caused by their products. Clearly, the
company failed to anticipate the growing chorus of public sentiment against it. And as
OxyContin incidents move closer to Washington and New York, pressure may increase on the
D.E.A. and the F.D.A. to take regulatory action against Purdue.
When I returned to the Gateway Rehabilitation Center outside Pittsburgh
earlier this month, I got a clearer sense of the way in which OxyContin is taking hold in
urban and suburban America. I also learned about an unexpected secondary effect of
OxyContin abuse: in cities like Pittsburgh, the crackdown on OxyContin is resulting in a
sharp rise in heroin abuse.
I sat for an afternoon in a glassed-in conference room, looking out on
Gateway's parking lot and groomed grounds, and talked with Andy and B., two addicts and
former low-level dealers. Before trying OxyContin, they had used their share of
recreational drugs, but they didn't consider themselves part of a hard-core drug
community. Aside from the track marks on his arms, B., 21, looked like every disaffected
college kid in America. He was a professional sloucher, dressed in an orange T-shirt, Army
shorts and sneakers, with a mop of brown hair. Andy wore a sparse goatee, a hooded Ecko
sweatshirt and a baseball cap with a Japanese character on it. I asked him what it meant,
and he said he didn't know.
B. began using OxyContin in 1998, when a friend told him about the
pills. He soon started dealing to support his habit, buying pills from a dozen or so
people and then selling them from his apartment to friends and friends of friends. His
sources were all legitimate pain patients, sick with cancer, carpal tunnel syndrome, lupus
or chronic back problems. But, as B. explained, they would often supplement their
OxyContin prescriptions with something weaker and cheaper, like Vicodin, then sell the
OxyContin and struggle through the month on Vicodin. "Some of them were old sick
ladies who've never done drugs," B. said. "They didn't understand what oxy can
do to people. They just knew they were getting $20 for each pill -- $1,800 a month off
something they can do without. They just wanted that money." Andy laughed. "Old
people are supposed to keep young people off drugs," he said.
B. described for me the casual feel of his drug deals. For the first
several months that he was selling OxyContin, he said, everything was friendly when he'd
go to pick up pills from his suppliers. "Most of them would say, 'Hi, honey come on
in.' You go into their house and sit down and have something to drink and talk for a while
and see how their family's doing, and they see how mine's doing. They were nice people. I
don't think they think of themselves as drug dealers." Nonetheless, B. said, his
suppliers kept most of the profits; he'd generally buy their pills for $20 apiece and then
sell them for $25.
About six months ago, B. said, as the police and news media began to
sound the alarm about OxyContin abuse, local doctors grew anxious. Many switched their
patients to harder-to-abuse fentanyl patches and morphine, and B. lost most of his
connections. The supply dried up, prices rose and people started ripping each other off.
A friend told him that shooting heroin was just like shooting
OxyContin, only cheaper. He'd never imagined that he might take heroin, but the expense of
OxyContin was killing him. "I was spending a hundred bucks a day on oxy," B.
said. "That's why I switched to heroin. You get really high off two bags, which is 30
bucks a day. That's a big savings." Andy agreed. It took him only a month and a half
to go from using OxyContin for the first time to shooting heroin, he said. "I've
always said that I'd never ever touch heroin. But then oxys came along and that's the same
thing, just cleaner. And that got me into shooting dope. If I'd never touched OxyContin, I
wouldn't have done heroin."
In Pittsburgh and its suburbs, Andy and B.'s stories aren't unique.
Gateway's doctors report a sharp increase in admissions of young heroin addicts who
started out on OxyContin. "Ninety percent of my friends that were addicted to oxys
are now addicted to heroin," B. said. "I know probably 30 or 40 heroin IV drug
users now because of OxyContin."
OxyContin entered the lives of casual drug users as a Trojan horse,
disguised as something it is not. It has never become a popular drug among existing heroin
or crack addicts, who already have a cheaper and at least as intoxicating mechanism for
getting high. OxyContin does the most damage when it enters a community of casual drug
users -- Curt's pot smokers and beer drinkers -- who think of pain pills as just another
interesting diversion for a Saturday night. In networks like Curt's or Paula's, before
OxyContin, no one ever did heroin or crack; those were seen as an entirely different
category of drug: something that will take over your life.
When you hold it in your hand, an OxyContin pill doesn't seem any
different than a Tylox or a Percocet or any of the mild narcotic preparations that have
for years seeped out of the pharmaceutical pipeline and into the lives of casual drug
users. What B. and Andy and Paula and Curt failed to realize is that despite appearances,
OxyContin actually belongs on the other side of the drug divide; it might look like a
casual Saturday-night drug, but it's a take-over-your-life drug. Rehab centers across the
country are filling up with young people who discovered that fact too late.
To Art Van Zee, the doctor who has seen his small community in western
Virginia "devastated" by OxyContin abuse, the answer to the crisis is to take
OxyContin off the market. Van Zee is circulating a petition asking the F.D.A. and Purdue
to withdraw the pill until a safer formulation can be found. "The bottom line is,
there's much more harm being created by this drug being available than good," he
says. "There are very good medicines available that are equally effective. We can
certainly meet people's pain needs without OxyContin."
But for many people, "drug communities" like Curt's are not
worthy of a whole lot of official sympathy or regulatory concern -- especially not when
their interests are considered next to those of patients in pain, who are using OxyContin
the way it is meant to be used and whose lives have been improved as a result. For doctors
who have seen their patients transformed by OxyContin, there is something mystifying, even
infuriating, about the suggestion that it should be withdrawn or even restricted, just
because a bunch of kids in Kentucky didn't know what they were snorting.
"There is no question that increasing opioid consumption for
legitimate medical purposes is going to lead to some increase in the rates of
addiction," Portenoy of Beth Israel says. "But the fact is, the tradeoff is
worth it. At the moment, the attitude is that if one housewife in Alabama becomes
addicted, then the drug must be pulled and the company shut down. But we're talking about
millions of people whose lives can be brought back from total disability by the proper use
of opioids. Any actions taken by law enforcement or the regulatory community that increase
the stigma associated with these drugs, or increase the fear of physicians in prescribing
these drugs, is going to exacerbate an already terrible condition and hurt patients."
The l0th point in Purdue Pharma's 10-point plan to reduce OxyContin
abuse is reformulation. The company says that it is spending millions of dollars to create
a new version of OxyContin, or perhaps a whole new medication, that would have all the
benefits of OxyContin and none of its dangers. Of all the initiatives under way, this is
the one that has received the most attention and created the most hope in Appalachia and
other affected areas.
In some interviews, Purdue's representatives sound downright
enthusiastic about this idea. Earlier this month, they put a price tag -- $50 million --
on the project for the first time. But when pressed, Haddox admits that what Purdue's
scientists are looking for is a "holy grail," a drug that will activate the
receptors in the brain that control pain relief and leave alone those that control
euphoria. And this isn't a new initiative, it turns out, but one that the company has been
working on for many years. Scientists and doctors as far back as Hippocrates have tried to
find a way to separate the benefits of opiates from their dangers.
There are often suggestions from Purdue that this reformulation may
take "a few years"; it's also entirely possible that it will never happen.
Opioids, including OxyContin, may remain the double-edged sword they have always been. And
regulators may simply decide to accept a certain amount of unintentional damage in the
treatment of pain, and leave local police chiefs and drug counselors -- as well as
individual addicts -- to find solutions to the OxyContin problem on their own. |